Introduction
Mature B-cell malignancies arise from B lymphocytes transformed at various developmental stages, thus accounting for the wide heterogeneity observed in the different disease entities. 1, 2 Analysis of surface antigens, of immunoglobulin (Ig) gene mutation status, and of global gene expression profiles facilitates the identification and classification of the normal B-cell counterpart. The somatic hypermutation status in Ig V genes has been used as an indicator that a B cell has reached or passed the germinal center (GC) stage of differentiation. 3, 4 It is still a matter of debate, whether this correlation is as clear and straightforward as originally thought, or whether B cells are able to gain Ig mutations and to switch isotypes outside of the classical GC/T-cell dependent pathway, that is in the extrafollicular zone of lymph nodes. [5] [6] [7] [8] Several groups now propose that the origin of some lymphoproliferative syndromes, that is chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL), mantle cell lymphoma (MCL), or marginal zone B-cell lymphoma (MZBL), lies in the marginal zone B cell. 9 The study of surface molecule expression has been used as another approach for the classification of B-cell malignancies. One of the molecules which defines B-cell developmental stages is CD27, a member of the TNFR superfamily. In fact, this molecule distinguishes two major B-cell subsets in adult peripheral blood: CD27À B cells, which correspond to naïve B cells, and CD27 þ memory B cells with somatically mutated Ig V genes. 10, 11 The memory B-cell population comprises isotype-class switched B cells and IgM þ IgD þ CD27 þ B cells, which express the same phenotype as B cells found in the marginal zone of the spleen and other lymphoid organs. 12 In the present report we describe JAM-C as a new molecule expressed on the surface of normal and malignant B cells. JAM-C is a type I protein, and a member of the junctional adhesion molecule family, which belongs to the Ig superfamily. 13 JAM-C expression is localized at the cell-cell junctions of endothelial cells of lymphatic sinuses, and of high endothelial venules of lymphatic organs. 13 In human tissues, it has also been described on smooth muscle cells and on hematopoietic cells, such as platelets, 14 and activated T cells. 15 JAM-C is also involved in tumor-induced angiogenesis, 16 as well as in leukocyte adhesion and transmigration during inflammation. 17 Our data show that JAM-C expression is regulated during B-cell maturation. Of particular interest, JAM-C expression divides CD27 þ B cells into two subpopulations: JAM-C þ cells, which constitute the major proportion of circulating CD27 þ cells in the peripheral blood, and JAM-CÀ cells, with a phenotype of GC B cells of secondary lymphoid organs. JAM-CÀ cells express high levels of BCL6, a nuclear proto-oncogene with a pivotal role in GC formation, 18 whereas JAM-C þ cells express a very low BCL6 level, a signature of extrafollicular cells. Simultaneous analysis of JAM-C and CD27 expression in peripheral blood lymphocytes (PBLs) allowed a clear classification into two types of B-cell malignancies: JAM-CÀ lymphomas (CLL, MCL, FL) and JAM-C expressing lymphomas (MZBL, HCL). We therefore suggest that JAM-C constitutes a new diagnostic marker for a more precise characterization of lymphoproliferative B-cell syndromes.
Materials and methods

Cell lines and cultured cells
BOSC, CHO and MDCK cells were obtained from the American type culture collection and cultured as described previously. 13, 19 HUVEC (Human umbilical vein endothelial cells)
were isolated by collagenase treatment and maintained in M199 medium supplemented with 10% fetal calf serum (FCS), endothelial cell growth supplement (15 mg/ml; Upstate Biotechnology, Charlottesville, VA, USA), heparin (4 mg/ml; Sigma, Buchs, Switzerland), hydrocortisone (0.1 mM; Sigma) and vitamin C (100 mg/ml; Sigma) as described. 20 
Constructs and expression vectors
Cloning of full-length human JAM-C cDNA from HUVEC has been described previously (accession number: AJ344431).
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Human soluble JAM-C cDNA including the two C and V extracellular domains was obtained by polymerase chain reaction (PCR) with a 5 0 -gctctagagacttccatctcctgctc-3 0 reverse primer introducing an XbaI site and a T7 primer, from the fulllength JAM-C cDNA. The purified amplified fragment was XbaI/ HindIII digested and cloned into the corresponding sites of a pcDNA3/FLAG vector. 22 Production of FLAG-tagged human soluble JAM-C 293T-derived BOSC cells were transiently transfected by calcium phosphate precipitation with the human soluble JAM-C pcDNA3 FLAGtagged plasmid. Supernatant in 0.3% bovine serum albumin (FractionV; Sigma) was harvested 7-10 days later and processed through an anti-FLAG M2 affinity column as described previously. 19 
Production of anti-JAM-C polyclonal antibody
A polyclonal anti-JAM-C antibody was manufactured by CovalAB (CovalAB, 69007 Lyon, France) by immunizing a rabbit with the soluble part of the human JAM-C molecule including the V and C domains. Specificity of the antiserum was assessed by (a) flow cytometry on CHO and MDCK cells, transfected with the full-length human JAM-C cDNA, and on HUVEC, used as a control for the detection of constitutive human JAM-C expression (Supplementary Figures 1 and 2) ; and (b) Western blots and immunoprecipitations on soluble JAM-C, wild-type MDCK cells, MDCK cells transfected with human JAM-C and HUVEC (Supplementary Figures 3 and 4) .
Human cell samples
Normal human tonsils, peripheral blood and bone marrow cells were obtained according to institutional guidelines. Blood and bone marrow samples from patients with a lymphoproliferative syndrome were analyzed as part of the routine diagnostic workup (Supplementary Table 1 ). Mononuclear cell suspensions were obtained after Ficoll enrichment.
Flow cytometry
After incubation with normal human serum, cell samples were incubated with the JAM-C rabbit antiserum at a 1/2000 dilution; reactivity was revealed with a human absorbed goat anti-rabbit IgG ¼ PE or IgG ¼ Alexa (Southern Biotechnology, Birmingham, AL, USA). Preimmune serum of the same rabbit at the same dilution was used as a control. Expression of JAM-C on human B lymphocytes C Ody et al performed according to standard procedures; samples were analyzed on a FacsCalibur (BD) using the Cellquest software. Dot-blot fluorescence-activated cell sorting (FACS) analyses were performed after gating on viable ( ¼ TO-PRO-3À) cells.
Cell cultures
Cell suspensions from tonsils were cultured either as such or as distinct FACS-sorted B-cell subpopulations (FACSARIA, BD; FACS core facility, CMU, University Hospital Geneva, Switzerland). Cells (10 4 /well) were cultured in 96-well plates with RPMI 1640 with Glutamine, supplemented with 10% FCS, 2% Hepes and 1% penicillin-streptomycin (all from GIBCO, Invitrogen, Basel, Switzerland) for 7 days. Cells were stimulated with cytokines (IL-2 (50 ng/ml) þ IL-4 (50 ng/ml) þ IL-10 (10 ng/ml)) and CD40L (10 mg/ml), or with cytokines and CpG (10 mg/ml). All reagents were purchased from Apotech (Epalinges, Switzerland).
Ig production analysis
Culture supernatants were tested by enzyme-linked immunosorbent assay for total Ig, IgM, IgG and IgA production, as described previously. 23 
Reverse transcription-PCR and real-time quantitative PCR
RNA was extracted using either Nucleospin columns (MachereyNagel, Oensingen, Switzerland) or Qia-shredder, followed by RNeasy minikit (Qiagen, Basel, Switzerland). For sorted cells, similar amounts of total RNA were reverse transcribed under the same conditions to ensure the same transcription efficiency. In all cases RNA integrity was assessed either by agarose gel or on an Agilent 2100 Bioanalyzer. RNA from MACS (Milteny, Biotec, Bergisch-Gladbach, Germany) purified CD19 þ B cells from healthy blood donors and from patients with lymphoproliferative syndromes was treated with DNAse, reverse transcribed with SuperScript II Reverse Transcriptase (Invitrogen) and Oligo(dT)15 primer (Promega, Madison, WI, USA), and amplified by PCR, using human JAM-C-specific primers (forward: 5 0 -ctggggaagacatccctgaag-3 0 ; reverse: 5 0 -agtgcggatgtagttaactcc-3 0 ), or human CD19-specific primers (forward: 5 0 -tcaacagatggggggcttctac-3 0 ; reverse: 5 0 -gggtcagtcattcgctttcttttc-3 0 ). PCR was performed on a GeneAmp PCR system 9700 (Perkin Elmer, Rotkreuz, Switzerland), with a 16 cycles touch down program from 62 to 541C and further 30 cycles at 541C.
Real-time reverse transcription (RT)-PCR using SYBR Green dye detection was performed to validate the relative change in gene expression between CD27 þ JAM-CÀ and CD27 þ JAM-C þ FACS-sorted tonsil cells, on an ABI prism SDS 7900 HT (Genomics Platform, CMU, Geneva). The primer sequences are available in Supplementary Table 2 . The 2 Â DNA Master SYBR Green I PCR mix (containing Taq DNA polymerase, dNTPs, and optimized buffer components; Applied Biosystems, Foster City, CA, USA) was used. Out of four tested, the two most stable house-keeping genes, beta-2-microglobulin and EEF1 (Eukaryotic translation elongation factor 1), were used as reference genes; in one experiment, a nonreverse transcribed sample was used as a control.
Results
The anti-human JAM-C polyclonal antibody recognizes a B-lymphocyte-specific antigen
In a previous report we have shown that an anti-murine JAM-C monoclonal antibody, which cross-reacts with the human homolog, detects an almost uniform pattern of JAM-C expression on PBLs and on CD19 þ cells. 21 Arrate et al. 15 did not detect JAM-C expression by Northern blot analysis of PBLs, but still detected it on samples from whole-spleen mRNA. To confirm our previous findings, we produced a polyclonal antihuman JAM-C antibody, obtained after immunization of a rabbit with the soluble part of the full-length human JAM-C molecule. After confirmation of the specificity of this antibody (see Supplementary Figures 1-4) , we analyzed normal CD19 þ B cells by FACS, and found a specific, albeit heterogeneous staining (Figure 1a) . Specificity of the antibody was assessed by competitive stainings with 100 mg/ml of purified, recombinant soluble JAM-C. The FACS data show that under these conditions, the JAM-C staining is abolished (Figure 1a ), whereas this is not the case when soluble JAM-B is added (data not shown). Considering the high JAM-C expression level on platelets, 14 and the possibility of passive transfer of JAM-C from platelet microparticles to B cells, 24 we performed parallel stainings with anti-CD41a: the weak contamination detected on some CD19 þ cells could in no way explain the observed JAM-C staining (data not shown). To unequivocally confirm the B-cell specificity of JAM-C expression, we purified B cells with anti-CD19-loaded microbeads and analyzed JAM-C mRNA levels by RT-PCR (Figure 1b Expression of JAM-C on human B lymphocytes C Ody et al
JAM-C distinguishes different B-cell subpopulations in normal human tonsils
Since the pattern of JAM-C expression detected on peripheral blood B cells was quite heterogeneous, with negative, low and high expressing cells, we devised multicolor stainings to characterize these B-cell subpopulations in more detail. We used cell suspensions from human tonsils, which contain large numbers of B lymphocytes, and analyzed CD27À and CD27 þ B cells for JAM-C expression. As shown in Figure 2a , three major B-cell populations can be clearly defined: JAM-CÀCD27 þ , JAM-C þ CD27 þ and JAM-C þ CD27À, whereby JAM-C expression is slightly stronger in the CD27 þ , than in the CD27À subpopulation. Staining with other markers (CD10, CD44 and CD38) expressed differentially by naïve and GC B cells, unequivocally identified JAM-C þ CD27À cells as naïve B cells, and JAM-CÀCD27 þ as GC B cells (Supplementary Figure 5) . JAM-C þ CD27 þ were identified as a heterogenous population including marginal zone and isotype-switched B cells.
In agreement with these results, analyses of these three subpopulations for IgD expression showed that JAM-CÀCD27 þ cells are preferentially IgDÀ, about 50% of the JAM-C þ CD27 þ cells stain positive for IgD, and JAM-C þ CD27À are preferentially IgD þ (Figure 2b-d) . Stainings for IgM showed similar results (data not shown). Therefore, JAM-C can be considered as a new surface marker for B lymphocytes, which divides the CD27 þ tonsillar B cells into two subpopulations: GC and non-GC B cells.
Ig production of cultured CD27/JAM-C-sorted B cells confirms their identity as naïve, GC and non-GC B cells
In short-term cultures of non-stimulated tonsil B cells, we observed a selective loss of JAM-CÀCD27 þ B cells after 7 days of culture, whereas the percentage of double positive non-GC B cells remained constant (Supplementary Figure 6) . This finding is probably explained by the high sensitivity of GC B cells to apoptotic stimuli. 25 In cultures stimulated with CD40L and cytokines (IL-2/IL-4/IL-10), viability of GC cells remained low (only 14% viable cells after 7 days of culture (Figure 3a) ) and cells did not proliferate. The two other tonsillar B-cell subpopulations, that is non-GC CD27 þ JAM-C þ and naïve, JAM-C þ CD27À B cells exhibited much higher viability rates, 56 and 71%, respectively (Figure 3a) . The expression of JAM-C remained almost constant in cultures of naïve B cells, whereas approximately one-third of the non-GC CD27 þ B cells lost JAM-C expression. This loss paralleled the acquisition of CD38, a marker indicative of B cell differentiation into plasmablasts. 
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The Ig production pattern of the three different B-cell populations is shown in Figure 3b . As expected, almost no Igs are detected in the supernatant harvested from naïve B cells, whereas GC and non-GC CD27 þ B cells produced high amounts of Ig. GC B cells preferentially secreted IgG and non-GC CD27 þ B cells IgM. Similar results were obtained with cultures stimulated with CpG and cytokines (data not shown).
JAM-C splits the CD27 þ B-cell population into BCL6 þ and BCL6À cells B cells were obtained from tonsils and sorted by FACS into CD27 þ JAM-C þ and CD27 þ JAM-CÀ populations. Real time-PCR was performed to find out, whether JAM-C expression selectively correlated with the expression of genes involved in GC formation, or B-lymphocyte adhesion and migration. The most striking difference between these two B-cell populations was the expression of the proto-oncogene BCL6, which was upregulated more than 10 times in JAM-CÀ cells, when compared to JAM-C þ cells (Figure 4) . This data assign a GC origin to the CD27 þ JAM-CÀ cells.
JAM-C expression is differentially regulated during B-cell development
To get a more precise overview of JAM-C expression during Bcell development, we have compared by flow cytometry, JAM-C expression on B-cell precursors from the bone marrow, naïve B cells from peripheral blood, B cells from tonsils and plasmocytes from the bone marrow. JAM-C is not expressed on immature CD10 þ CD19 þ B cells in the bone marrow (Figure 5a ). JAM-C expression starts on mature, naïve B cells, which constitute the majority of circulating B cells (Figure 5b 
Expression of JAM-C in B-cell malignancies
B-cell malignancies arise from B lymphocytes transformed at different developmental stages. We therefore studied JAM-C expression in various lymphoproliferative syndromes to identify deregulated expression associated with a specific disease and to correlate the disease to a specific developmental stage. In addition, we studied expression of CD44, another marker of B-cell differentiation. 26 Striking examples of the absence of correlation between JAM-C and CD44 expression in lymphoproliferative syndromes are shown in Figure 6a . In CLL, B cells are JAM-CÀ and CD44 þ , whereas in most cases of MZBL, they are JAM-C þ and CD44 þ . To confirm these findings, JAM-C mRNA expression was studied in PBLs cDNA from one patient with CLL and one patient with MZBL (Figure 1b) . The results correlated with our FACS data, which showed very few JAM-C þ cells in the CLL sample, and more than 86% of JAM-C þ cells in the MZBL sample. The differential expression between CD44 and JAM-C is also noted in Multiple Myeloma. Figure 6b gives a summary of all the cases studied so far. 
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Discussion
Expression of the junctional adhesion molecule C is not restricted to endothelial cell-cell junctions. 13 As already described in previous studies, it is also found on hematopoietic cells, such as platelets 14 and activated T cells. 15 In the present study we show that JAM-C is also expressed on human B lymphocytes, in particular on a subset of CD27 þ B cells and that its expression changes during B-cell differentiation. Moreover, JAM-C expression in lymphoproliferative syndromes is disease specific and allows to divide these diseases into JAM-C and JAM-C þ groups.
According to our data, expression of JAM-C during B-cell differentiation can be summarized as follows: immature, JAM-CÀ B cells in the bone marrow develop into mature, naïve IgD þ IgM þ CD27À B cells, which express JAM-C. When these cells are stimulated in lymph follicles, they can engage in a GC reaction and develop into plasma cells or memory B cells (CD27 þ B cells).
11 JAM-C expression allows identification of B cells in these different developmental steps. Of particular interest is the GC stage, characterized by the loss of JAM-C expression of naïve B cells, the simultaneous downregulation of CD44, and the strong expression of CD10 and CD38, as well as of BCL6. When GC cells develop into post-germinal CD27 þ memory B cells, JAM-C gets re-expressed, with a typical high expression compared to naïve B cells. In addition to these 'classical' memory cells, IgM þ IgD þ CD27 þ memory B cells also show this high expression of JAM-C. This developmental scheme is supported by the profiles of Ig secretion. In fact, both CD27 þ subsets respond in vitro to CD40L stimulation by Ig secretion. In contrast, CD27À naïve B cells do not secrete Ig (Figure 3b ). Whereas JAM-C þ GC B cells mainly secreted IgG, the dominant Ig subclass secreted in JAM-C þ cells was IgM.
Both MCL and CLL have originally been considered to be derived from naïve pre-GC cells, 27, 28 but studies performed within the last 5 years on the mutation status of V genes and on gene expression have raised some doubt on this hypothesis. 29 Some authors have discussed the possibility for an extrafollicular, marginal zone origin for both diseases. 9 Our data argue against this possibility, since both disease entities are JAM-CÀ. In view of the high affinity described for the formation of JAM-C/ JAM-B heterodimers in cell-cell contact, 15 JAM-C could constitute a B-cell activation marker induced by interaction with JAM-B molecules present on tonsilar stroma. 30 Failure to express this molecule could point to the origin of the maturation block of CLL and MCL. Similar to what has been reported during spermatid maturation, where JAM-C expressing spermatids interact with JAM-B expressing Sertoli cells to achieve maturation, 31 an analog interaction could be necessary between JAM-C expressing B cells and JAM-B, for the maturation from GC to post-GC B cell (or directly from naïve to memory B cells via the GC-independent pathway). On the other hand, it cannot be excluded that the absence of JAM-C on CLL and MCL cells correlates to mutational events in the pathogenesis of these lymphomas, independent of the developmental stage of the original B cell. Detailed gene expression studies of the different Expression of JAM-C on human B lymphocytes C Ody et al normal B-cell subpopulations and B-cell tumor cells could help to clarify this issue. We found that ZAP-70 þ and ZAP-70À cases of CLL are both JAM-CÀ. This finding is in accordance with the results from gene expression studies, which show that both subtypes of CLL have a common gene expression profile and that CLL is a homogenous disease despite genotypic (IgV gene mutational status and genomic alterations) and clinical differences. 32, 33 In contrast to CLL and MCL, we found that HCLs (6/6 cases) and 75% of MZBL (9/12 cases) express JAM-C as strongly as normal CD27 þ B cells. According to the current hypothesis, HCL and MZBL originate from B cells of the marginal zone. 9, 34 Our findings fit well with this hypothesis, if we consider simultaneous staining with CD27 and JAM-C as a characteristic feature of marginal zone B cells.
Whereas current diagnostic antibody panels allow in most cases of B-cell malignancies a clear diagnosis, 'borderline' cases exist, where despite extensive phenotypic characterization a definitive classification cannot be obtained. This is particularly true for CLL, MZL and MZBL. These three lymphoma entities have a similar clinical presentation and histology, although a different clinical outcome. Addition of JAM-C to the traditionally used CD5, CD10, CD23 and CD43 antibody panel will lead to a better distinction between these three diseases, since JAM-C is not expressed in CLL, whereas it constitutes a positive marker in 75% of MZBL. It remains debatable whether the three Expression of JAM-C on human B lymphocytes C Ody et al JAM-CÀ MZBL cases of our series were 'bona fide' MZBL, or rather misdiagnosed MZBL, corresponding instead to CD5À, atypical CLL. This distinction was impossible for us to make in the absence of any specific chromosomal translocation or any other specific marker. Alternatively, this difference could correlate to the mutation status of IgV genes (in one study of 23 MZBL patients only 66% showed mutated Ig 35 ), or correspond to different subgroups of MZBL. As expected, FL cases did not express JAM-C in accordance with the GC origin of FL cells. On the other hand, we hypothesize that the heterogeneous expression in the diffuse large B-cell lymphoma (DLBL) cases reflects the heterogeneous origin of these cells: either GC or post-GC. Analyses of gene expression patterns could help to clarify this issue.
Currently we do not know how the expression of JAM-C in the different LPSs correlates to survival. A much larger cohort of patients with a long follow-up of several years would be needed to answer this question.
In summary, we have described JAM-C as a new surface marker of human B lymphocytes. Its expression is tightly controlled during normal B-cell differentiation. We have shown that the differential expression level of this molecule defines two subpopulations of CD27 þ B cells, namely the JAM-CÀ GC and the JAM-C þ non-GC B cells. According to this differential expression, the different lymphoproliferative syndromes can be clearly classified according to the presence or absence of JAM-C from the B-cell surface. In particular, our data show that the simultaneous positivity for CD27 and JAM-C could constitute a characteristic feature of non-GC B-cell lymphomas such as MZBL.
